MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
GRFS stock logo

GRFS

Grifols, S.A.

$10.16
0.08
 (0.79%)
Exchange:   NASDAQ
Market Cap:   8.595B
Shares Outstanding:   421.254M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Jose Ignacio Abia Buenache
Full Time Employees:  23833
Address: 
Avinguda de la Generalitat, 152
Barcelona
8174
ES
Website:  https://www.grifols.com
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumΒ–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoringΒ–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Click to read more…

Revenue Segmentation

πŸ”’ You are currently logged out

Login

EPS

πŸ”’ You are currently logged out

Login
View full analyst estimates

Earnings Call

πŸ”’ You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Current Key Metrics

πŸ”’ You are currently logged out

Login

Forward P/E Ratios

πŸ”’ You are currently logged out

Login

SWOT Analysis

πŸ”’ You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

πŸ”’ Premium Feature

Log in to access the GRFS Intrinsic Value Calculator

πŸ”‘ Log In
πŸ“ Sign Up Free

Get comprehensive stock analysis with premium features

πŸ”’ You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news

20-08-2025 10:41
Are Investors Undervaluing Grifols (GRFS) Right Now?